Takeda Pharmaceutical Company held two meetings for scientific exchange and sharing experiences in relation to Hodgkin Lymphoma. The meetings consisted of a regional summit which was conducted on the 17th January, followed by a Centre of Excellence in the Bone Marrow Transplantation Unit of the Air force Specialized Hospital on 18th of January. The two meetings were attended by the world's leading experts from Germany, Denmark, Spain, different Arab and African countries and our Egyptian experts. The summit on the 17th of January was a scientific platform to discuss the latest updates about Hodgkin lymphoma disease and its management in different stages to exchange different scientific standards of medical practice. The second day, 18th of January, was a scientific forum to exchange experiences of the Centre of Excellence for Bone Marrow Transplantation in cooperation with the Air force Specialized Hospital, to increase the efficiency of the treatment of the Egyptian patient, which is the primary goal of Takeda. Dr. Hossam Kamel, the former president of Cairo University and pioneer of “Bone Marrow transplantation ” in Egypt, confirmed that Hodgkin lymphoma can be detected and treated in the early stages, especially in the light of recent developments by relying on targeted therapy, immunotherapy and marrow transplantation operations, adding that the world is heading to establish standards and recommendations on how to rationalize the use of chemotherapy in the treatment of this disease in order to avoid its negative side effects. "Dr. Martin Hutchings, consultant of blood diseases at Copenhagen University Hospital in Denmark, said: “These scientific events are a great opportunity to learn about the latest international medical research to address this disease, as well as to identify the vision of European, American and Egyptian medical schools for treatment methods." Dr. Iman Gamal, Director of the Middle East and North Africa, Takeda Medical department added that this is an on-going scientific cooperation between Takeda and the medical community in Egypt. This will allow the Egyptian practitioners to have continuous medical education and information update with the latest research in the field of Hodgkin lymphoma. The program also aims to raise the level of Medical service provided to the Egyptian patient from diagnosis to treatment and follow-up. She clarified that this scientific platform conducted on January 17 is in cooperation with the Egyptian Haemato-Oncology Group (EHOG) which will honour Dr. Ayman Mekkawy for his media efforts to increase health awareness among the Egyptian society.
